Why We Do It
We are invested in making a meaningful difference in the lives of patients and their families around the globe.
We do this by advancing innovative solutions for clinical practice that are sustainable, cost-effective and accessible.
“We wouldn’t be alive today without Fogarty Innovation.”
– Company-In-Residence CEO
At our core…
We behave with integrity first and foremost, knowing we affect the lives of patients and their loved ones.
We put team before self, valuing mutual trust and respect for each other, and sharing a foundational belief that strong teams enhance performance.
We believe in equality and seek diversity to keep growing as a team — not only in race and gender, but also in expression.
We value continuous learning, both as teachers and perpetual students.
We believe the process of innovation is a discipline that can be taught and honed.
We trust in the power of an audacious vision because it taps into a basic human desire: belonging to and believing in something bigger than ourselves.
We have a sense of wonder and a spirit of adventure as we push boundaries to create positive impact on the global medical ecosystem.
We stay humble for all that remains to be done in shaping the future of human health.
We believe these things because we have seen the power of their impact
HeartFlow, Fogarty Innovation’s first company-in-residence, is also its first graduate to go public. The company did this through a special purpose acquisition company (SPAC) merger with Longview Acquisition Corp. II valued at $2.4B, with an estimated $400 million in...
Fogarty graduate EchoPixel helped revolutionize heart surgery with its True3D, a turnkey surgical planning software that creates a hologram of the heart for study before an incision is ever made. With FDA 510(k) clearance, True3D has already been implemented by more...
PQ Bypass, one of the first Fogarty Innovation startups, was recently acquired by Endologix LLC, a leader in the treatment of vascular disease. The addition of the PQ Bypass technology portfolio, which targets the treatment of complex superficial femoral artery (SFA)...